The transdermal delivery system is one of the best routes for new drug delivery system. Transdermal drug delivery gives more advantages over conventional delivery methods including oral and injection methods. The generally transdermal drug delivery system uses a patch containing drug substance enter via the skin, is convenient and painless, and avoids gastrointestinal toxicity (e.g. peptic ulcer disease) and avoids the therapeutic first pass metabolism. Transdermal drug delivery is rarely an old technology since 1800's and the technology is no longer just adhesive patches. The novel improvement in technology and the tendency to applying on the skin without irritation to the site of action, the transdermal route is becoming a most widely accepted route of drug administration (Jamaandi et al., 2009).
time of irritation or termination of therpy (Murthy et al., 2008) . At present study most of the drugs are taken orally but, they are not found to be as effective to the patient. So to improve the activity of such drug through the TDDS (Das et al., 2006) . Diabetes mellitus is a fastly growing health problem in worldwide and an important cause of prolonged ill health and causes to early death. It is a chronic metabolic disorder characterized by a high blood sugar concentration (hyperglycaemia) caused by deficiency of insulin. The requirement for transdermal film of saxagliptin is additional justified suitable to the need for maintaining unfluctuating plasma concentrations, for the effective management of blood sugar for long period in diabetic patients (Aurora and Mukherjee, 2009 ).
The main target of transdermal formulation dosage form design is to increases the drug permeability through the skin into the systemic circulation & simultaneously decreases the retention and metabolism of the drug in the skin. The formulation of the transdermal patch by using various polymers, plasticizer, penetrant & solvent was prepared. This formulated transdermal patch is used for the treatment of type 2 diabetes (Vandana and Rachna, 2011) 
Materials and Methods

Materials
Saxagliptin was obtained as a gift sample from MSN Laboratories, Hyderabad. HPMC and PVP are purchased from SD fine-chem. Limited, world road Mumbai, India. Dibutyl phthalate, DMSO, Methanol purchased from LOBA CHEMIE Tarapur MIDC, palghar, Maharashtra (India). All other chemicals were of analytical grade.
Formulation of Saxagliptin Loaded Transdermal Patch
Formulations of Saxagliptin patch by using solvent evaporation technique. Formulation of the transdermal patch polymers was weighed in requisites ratio of HPMC and PVP. The polymer mentioned above is dissolved in methanol followed by addition of Dibutyl Phthalate and DMSO in methanol and the mixture was homogenized. Addition of accurate quantity of Saxagliptin (10 mg) in polymeric solution and sonicate the mixture to avoid the lumps. The above solution was poured into polyurethane coated Petri plate used in bangles. After pouring a solution in Petri plate was kept for drying 24 hrs at room temperature. Inverted glass funnel was placed on petri plate for controlling solvent evaporation rate. After drying patch were removed & wrapped in aluminum foil and store in desiccators until further use (Manjusha et al., 2011) ( Table 1) .
Characterization of medicated polymeric patch
Physical appearance
All the transdermal patches were visually inspected for color, clarity, smoothness and flexibility.
Surface pH
The patches were allowed to swell by keeping them in contact with 0.5 ml of double distilled water for 1 hour in glass tubes. The surface pH was determined by using pH paper.
Thickness
The thickness of the film was measured by using Micrometer Screw Gauze. The thickness uniformity was measured at three different sites and an average of three readings was taken with standard deviation.
Folding endurance
A 4 cm area of the strip is cut and repeatedly folded at the 2 same place till it broke. The number of times the film could be folded without breaking gave the value of folding endurance.
Flatness
For flatness determination, one strip was cut (2 cm ) from 2 the center and two from each side of patches. The length of each strip was measured and the difference in length was measured by determining percent constriction. It was calculated by using following formula:
Where, L1 = initial length of each strip, L2 = final length of each strip.
Weight uniformity
Five films were cut (2 cm ) from each batch and weighed on 2 electronic balance for weight variation test. The test was done to check the variation of weight and thus to check the www.ajpp.in Table 1 . Composition of various formulations Sr.
No.
Name of Ingredient Formulations F1 F2 F3 F4 F5 F6
1 Saxagliptin(mg) 10 10 10 10 10 10 2 Methanol(ml) 10 10 10 10 10 10 batch-to-batch variation.
Tensile strength
To determine the tensile strength of transdermal patches, the polymeric films in the transdermal patch were sandwiched individually by corked liner iron plates. One end of the patch was kept fixed with the help of iron screen and another end was connected to a freely movable thread over a pulley. The weight increased slowly to the pan close with the hanging end of the thread. A pointer on the thread used to measure the elongation of the film. The weight just sufficient to break the film was noted, the tensile strength was calculated using the following equation.
Tensile strength = Maximum applied force/ Minimum crosssectional area
Where, m-Mass in kg; g-Acceleration due to gravity at 980 cm/ sec
Drug content
As with all controlled release drug delivery systems, the final product evaluated for a TDDS must include content uniformity determinations. This test involves the assay of individual units of a specified number of dosage forms in order to determine homogeneity in their content. The film which was used for weight variation was evaluated for their drug content individually. The drug-containing films were dissolved in sufficient quantity of methanol and volume was made up to 10 ml with phosphate buffer pH 7.4. From this 1 ml was withdrawn and diluted to 10 ml with solvent and the drug content was determined spectrophotometrically. Based on the concentration obtained and the dilution factor, the drug content in each film was calculated.
In-vitro skin permeation study
In-vitro drug permeation studies were performed by using a franz diffusion cell (Area = 28.26 cm ) with a receptor compartment 2 capacity of 60 mL. The Human Cadaver skin was mounted between the donor and receptor compartment of the franz diffusion cell. The prepared patches were applied on the skin & covered with aluminium foil as a backing membrane. The receptor compartment of the franz diffusion cell was filled with phosphate buffer pH 7.4. The assembly was put on a magnetic stirrer and the solution was continuously stirred using magnetic beads at 50 rpm, and the temperature 37 ± 0.5°C was maintain throughout the study. The samples were withdrawn at fixed time intervals to check for drug content by spectrophotometrically. The receptor phases were replenished with an equal volume of phosphate buffer pH 7.4 at each sample withdrawal and the drug in -vitro permeation through human cadaver skin was determine (Samip et al., 2010) .
Results and discussion
In a preformulation study of saxagliptin the colour, odour, appearance and melting point was determined ( Table 2 ).
The thickness of the patches was found to be in the range 0.234 ± 0.020 to 0.308 ± 0.030 mm. The surface pH of all the formulation was found to be in the range of 6.14 ± 0.09 to 6.52 ± 0.07 which coincide with a pH range of skin and hence can be concluded that no skin irritation should be occur. The folding endurance of transdermal patches was measured manually. The folding endurance of the patches was found to be in the range of 112 ± 11.50 to 190 ± 14.97. The patches would not break and would retain their integrity with general skin folding when applied on the skin. The weight uniformity of formulated patches was found to be in the range of 20.58±0.46 to 24.89±0.56 mg. The Flatness studies showed that some of the formulations had the differences in the length before and after their cuts. It www.ajpp.in indicates percent constriction and almost 100 % flatness in all formulations. The tensile strength of the patches varies with the concentration of polymers. It was found to be between 1.163 ± 0.07 to 1.821 ± 0.06 kg/cm . The results are shown in Table 3 ). In 2 ( comparisons of all formulation F6 show the best results.
The drug content varied between 94.06% ± 0.62 to 98.69% ± 0.20 of the drug incorporated in the formulations. Formulation F6 shows maximum drug content (98.69% ± 0.20).
skin In -vitro permeation study for transdermal patch, was performed for 7 hrs using excised human cadaver skin. Transdermal flux for different patches formulation was calculated and was found in the range of 4.76 ± 0.080 to 26.41 ± 0.035 /hr. Flux for F6 μg/cm 2 formulation was 6 times greater than that of the F5 formulation (see Table 4 & Figure 1 ). The F6 formulation is considered as the best and optimized formulation from thickness, surface pH, weight uniformity, flatness, drug content, folding endurance and in vitro permeation study results. Conclusion Transdermal drug delivery system was developed by using Saxagliptin as a drug. The rationale behind choosing this drug was that all physicochemical properties of the drug were suitable for administering the drug via transdermal route. The transdermal patches were prepared by a solvent evaporation method. The prepared patches were evaluated for thickness, surface P weight uniformity, flatness, drug content, H, folding endurance and permeation study across in-vitro excised human cadaver skin.
The formulated patches had good appearance and physical characteristics (no cracks, uniform thickness, mass and drug content) and showed high characteristics. The optimized HPMC (100%) patches (Formulation F ) showed 6 the highest drug permeation flux and drug content.
in -vitro
The obtained results suggested that the formulations can be promising therapeutic systems for the transdermal delivery of Saxagliptin to avoid the problem associated with parenteral and oral route. 
